The American Society of Hematology (ASH) annual meeting is being held December 1-4, 2018 in San Diego, CA. There is a guide at: xconomy.com/national/2018/1...
ASH 2018: A Guide to the Latest for Blood-Born... - CLL Support
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
![wmay13241 profile image](https://images.hu-production.be/avatars/d14f47ddf579160ff686f7facc9d2346_small@2x_100x100.jpg)
Written by
![wmay13241 profile image](https://images.hu-production.be/avatars/d14f47ddf579160ff686f7facc9d2346_small@2x_100x100.jpg)
wmay13241
To view profiles and participate in discussions please or .
Read more about...
8 Replies
•
Thank you, very helpful!
Imbruvica saved my life!
Thanks.
![Jm954 profile image](https://images.hu-production.be/avatars/07d4983fe0890fcbf98136b84b1525ae_small@2x_100x100.jpg)
Jm954Administrator
I would love to go .......
My wife’s haematologist from Melbourne, Australia attending this to hear more about ibrutinib plus rituximab combination. Wife starting on ibrutinib after he gets back for she didn’t respond positively to 2 cycles of FCR.
First diagnosed with NHL (SLL) in 2008, treated with CHOP+R then returned as CLL in 2013, treated with CVP+R, now returned 2018. Also been receiving IgG infusions regularly.
Let’s hope the ASH conference reports plenty of encouraging options.
Not what you're looking for?
You may also like...
ASH 2018 and More
Hi,
This is the most exciting, hectic and rewarding time of the year for the CLL Society, as we are...
ASH 2018: Dr. Lindsey Roeker research from ASH 2018 on real world use of venetoclax for CLL
Today we posted on ASH 2018: Dr. Lindsey Roeker research from ASH 2018 on real world use of...
ASH 2018: Dr. Kipps on antibodies and Venetoclax resistance
Venetoclax was changed how we treat CLL, but it doesn't work for everyone and it doesn't always...
ASH 2018: Dr. Lindsey Roeker, on real world use of venetoclax for CLL (chronic lymphocytic leukemia)
Is venetoclax as safe and effective in the real world as compared to clinical trials? Read my ASH...
ASH 2018: ECOG trial shows superiority of Ibrutinib and rituximab over FCR
Hi friends,
The early buzz at ASH 2018 was rightly about the ECOG trial that was presented on the...